ArticleIndian dermatology online journal2026
Unmasking the Hidden Risk: Urticaria and Angioedema with Direct Oral Anticoagulants.
Article in Indian dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractDirect oral anticoagulants (DOACs), such as rivaroxaban and dabigatran, are widely used for thromboembolic conditions. While bleeding is the most well-recognized adverse effect, rare cutaneous hypersensitivity reactions, such as urticaria and angioedema, are increasingly reported. We describe a case series of nine patients who developed cutaneous hypersensitivity reactions to DOACs. All patients developed symptoms within 1-10 days of DOAC initiation. Rivaroxaban was associated with angioedema and urticaria, whereas dabigatran was limited to urticaria. All reactions resolved after drug discontinuation and symptomatic treatment. Dermatologic adverse effects of DOACs, although uncommon, warrant heightened clinical suspicion. A limitation of this study is the small sample size and absence of rechallenge confirmation of hypersensitivity. Management should be individualized. Increased awareness among dermatologists and physicians is crucial for timely management and pharmacovigilance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.